BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

The founders of Inventiva S.A.S. are using a platform from predecessor company Laboratoires Fournier S.A. to discover small molecules that target epigenetic enzymes, transcription factors and nuclear receptors for oncology, fibrosis and autoimmune disease. The...
BC Week In Review | Mar 17, 2014
Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

Sinclair said FDA granted Orphan Drug designation to Flammacerium cerium nitrate/silver sulfadiazine cream to treat patients with severe dermal burns. The company said the product is used in cases where surgical excision and grafting are...
BC Week In Review | Sep 9, 2013
Company News

CordenPharma International GmbH, Solvay deal

Contract manufacturing provider CordenPharma will acquire Solvay's Peptisyntha S.A. business, which manufactures custom peptides for pharmaceutical use. The deal, which does not include U.S. sister company Peptisyntha Inc., is expected to close later this fall....
BC Week In Review | Jun 24, 2013
Company News

AbbVie, Actavis, Solvay generics, genitourinary news

The U.S. Supreme Court ruled in Federal Trade Commission v. Actavis Inc., et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a ruling by...
BC Extra | Jun 18, 2013
Top Story

SCOTUS: pay-for-delay subject to antitrust litigation

The U.S. Supreme Court ruled on Monday in Federal Trade Commission v. Actavis Inc. , et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a...
BC Week In Review | Jun 10, 2013
Company News

AbbVie sales and marketing update

AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The product comprises a combination of porcine-derived lipases, proteases and amylases. The wholesale acquisition cost of...
BC Extra | Mar 27, 2013
Politics & Policy

SCOTUS hears oral arguments in pay-for-delay

Comments from the U.S. Supreme Court Justices at Monday's Actavis Inc. , et al. suggest pay-for-delay settlements between branded and generic drug manufacturers could face heightened judicial scrutiny, but perhaps not to the extent the FTC...
BC Week In Review | Mar 25, 2013
Company News

Sinclair IS Pharma, Hikma Pharmaceuticals sales and marketing update

Under a 10-year deal, Sinclair granted Hikma exclusive rights to commercialize Flammacerium in 18 countries within the Middle East and North Africa region. The first launches are expected in late 2014 or early 2015. The...
BC Week In Review | Dec 17, 2012
Company News

Abbott, Par Pharmaceutical, Perrigo, Watson endocrine/metabolic news

The U.S. Supreme Court agreed to review a decision from the U.S. Court of Appeals for the Eleventh Circuit that upheld a pay-for-delay deal between branded and generic drug manufacturer as not in violation of...
BC Week In Review | Dec 10, 2012
Company News

Medigene, Nordic Group sales and marketing update

Nordic's Nordic Pharma received exclusive rights to commercialize Veregen to treat genital warts in the Czech Republic, Slovakia, Poland, Hungary, Baltic countries, Georgia and the Commonwealth of Independent States (CIS). Medigene is eligible for milestones,...
Items per page:
1 - 10 of 434
BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

The founders of Inventiva S.A.S. are using a platform from predecessor company Laboratoires Fournier S.A. to discover small molecules that target epigenetic enzymes, transcription factors and nuclear receptors for oncology, fibrosis and autoimmune disease. The...
BC Week In Review | Mar 17, 2014
Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

Sinclair said FDA granted Orphan Drug designation to Flammacerium cerium nitrate/silver sulfadiazine cream to treat patients with severe dermal burns. The company said the product is used in cases where surgical excision and grafting are...
BC Week In Review | Sep 9, 2013
Company News

CordenPharma International GmbH, Solvay deal

Contract manufacturing provider CordenPharma will acquire Solvay's Peptisyntha S.A. business, which manufactures custom peptides for pharmaceutical use. The deal, which does not include U.S. sister company Peptisyntha Inc., is expected to close later this fall....
BC Week In Review | Jun 24, 2013
Company News

AbbVie, Actavis, Solvay generics, genitourinary news

The U.S. Supreme Court ruled in Federal Trade Commission v. Actavis Inc., et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a ruling by...
BC Extra | Jun 18, 2013
Top Story

SCOTUS: pay-for-delay subject to antitrust litigation

The U.S. Supreme Court ruled on Monday in Federal Trade Commission v. Actavis Inc. , et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a...
BC Week In Review | Jun 10, 2013
Company News

AbbVie sales and marketing update

AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The product comprises a combination of porcine-derived lipases, proteases and amylases. The wholesale acquisition cost of...
BC Extra | Mar 27, 2013
Politics & Policy

SCOTUS hears oral arguments in pay-for-delay

Comments from the U.S. Supreme Court Justices at Monday's Actavis Inc. , et al. suggest pay-for-delay settlements between branded and generic drug manufacturers could face heightened judicial scrutiny, but perhaps not to the extent the FTC...
BC Week In Review | Mar 25, 2013
Company News

Sinclair IS Pharma, Hikma Pharmaceuticals sales and marketing update

Under a 10-year deal, Sinclair granted Hikma exclusive rights to commercialize Flammacerium in 18 countries within the Middle East and North Africa region. The first launches are expected in late 2014 or early 2015. The...
BC Week In Review | Dec 17, 2012
Company News

Abbott, Par Pharmaceutical, Perrigo, Watson endocrine/metabolic news

The U.S. Supreme Court agreed to review a decision from the U.S. Court of Appeals for the Eleventh Circuit that upheld a pay-for-delay deal between branded and generic drug manufacturer as not in violation of...
BC Week In Review | Dec 10, 2012
Company News

Medigene, Nordic Group sales and marketing update

Nordic's Nordic Pharma received exclusive rights to commercialize Veregen to treat genital warts in the Czech Republic, Slovakia, Poland, Hungary, Baltic countries, Georgia and the Commonwealth of Independent States (CIS). Medigene is eligible for milestones,...
Items per page:
1 - 10 of 434